190 related articles for article (PubMed ID: 30704537)
1. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study.
Sakr FA; Grothe MJ; Cavedo E; Jelistratova I; Habert MO; Dyrba M; Gonzalez-Escamilla G; Bertin H; Locatelli M; Lehericy S; Teipel S; Dubois B; Hampel H; ;
Alzheimers Res Ther; 2019 Jan; 11(1):15. PubMed ID: 30704537
[TBL] [Abstract][Full Text] [Related]
2. In vivo staging of regional amyloid deposition.
Grothe MJ; Barthel H; Sepulcre J; Dyrba M; Sabri O; Teipel SJ;
Neurology; 2017 Nov; 89(20):2031-2038. PubMed ID: 29046362
[TBL] [Abstract][Full Text] [Related]
3. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal validity of PET-based staging of regional amyloid deposition.
Jelistratova I; Teipel SJ; Grothe MJ
Hum Brain Mapp; 2020 Oct; 41(15):4219-4231. PubMed ID: 32648624
[TBL] [Abstract][Full Text] [Related]
5. Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint.
Thomas KR; Weigand AJ; Edwards LC; Edmonds EC; Bangen KJ; Ortiz G; Walker KS; Bondi MW;
Alzheimers Res Ther; 2022 Aug; 14(1):114. PubMed ID: 35996158
[TBL] [Abstract][Full Text] [Related]
6. In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease.
Teipel SJ; Dyrba M; Chiesa PA; Sakr F; Jelistratova I; Lista S; Vergallo A; Lemercier P; Cavedo E; Habert MO; Dubois B; Hampel H; Grothe MJ;
Neurobiol Aging; 2020 Sep; 93():98-108. PubMed ID: 32291113
[TBL] [Abstract][Full Text] [Related]
7. Multitracer model for staging cortical amyloid deposition using PET imaging.
Collij LE; Heeman F; Salvadó G; Ingala S; Altomare D; de Wilde A; Konijnenberg E; van Buchem M; Yaqub M; Markiewicz P; Golla SSV; Wottschel V; Wink AM; Visser PJ; Teunissen CE; Lammertsma AA; Scheltens P; van der Flier WM; Boellaard R; van Berckel BNM; Molinuevo JL; Gispert JD; Schmidt ME; Barkhof F; Lopes Alves I; ;
Neurology; 2020 Sep; 95(11):e1538-e1553. PubMed ID: 32675080
[TBL] [Abstract][Full Text] [Related]
8. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
[TBL] [Abstract][Full Text] [Related]
10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
11. In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease.
Levin F; Jelistratova I; Betthauser TJ; Okonkwo O; Johnson SC; Teipel SJ; Grothe MJ
Alzheimers Res Ther; 2021 Oct; 13(1):178. PubMed ID: 34674764
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
13. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.
Biel D; Brendel M; Rubinski A; Buerger K; Janowitz D; Dichgans M; Franzmeier N;
Alzheimers Res Ther; 2021 Aug; 13(1):137. PubMed ID: 34384484
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Brain Amyloid Measures Predict Time-to-Progression from Amnestic Mild Cognitive Impairment to Alzheimer's Disease.
Jun S; Kim H; Kim BS; Yoo BG; Lee WG;
J Alzheimers Dis; 2019; 70(2):477-486. PubMed ID: 31256127
[TBL] [Abstract][Full Text] [Related]
16. Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study.
Teipel SJ; Cavedo E; Lista S; Habert MO; Potier MC; Grothe MJ; Epelbaum S; Sambati L; Gagliardi G; Toschi N; Greicius MD; Dubois B; Hampel H; ;
Alzheimers Dement; 2018 Sep; 14(9):1126-1136. PubMed ID: 29792873
[TBL] [Abstract][Full Text] [Related]
17. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
19. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
20. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
